Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 8:52 pm Purchase |
2023-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV |
Venrock Healthcare Capital Partners III, L.P. | 4,824,731 14.000% |
1,251,017 (+35.01%) |
Filing History |
| 2024-02-14 8:51 pm Purchase |
2023-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT |
Venrock Healthcare Capital Partners III, L.P. | 4,400,000 8.900% |
1,512,483 (+52.38%) |
Filing History |
| 2024-02-14 8:47 pm Purchase |
2023-12-31 | 13G | Spyre Therapeutics, Inc. SYRE |
Venrock Healthcare Capital Partners III, L.P. | 3,734,514 9.990% |
3,734,514 (New Position) |
Filing History |
| 2024-02-14 8:45 pm Purchase |
2023-12-31 | 13G | Praxis Precision Medicines, Inc. PRAX |
Venrock Healthcare Capital Partners III, L.P. | 823,626 8.900% |
823,626 (New Position) |
Filing History |
| 2024-02-14 8:44 pm Purchase |
2023-12-31 | 13G | RayzeBio, Inc. Common Stock RYZB |
Venrock Healthcare Capital Partners III, L.P. | 4,030,471 6.700% |
13,624 (+0.34%) |
Filing History |
| 2024-02-14 8:44 pm Sale |
2023-12-31 | 13G | Taysha Gene Therapies, Inc. TSHA |
Venrock Healthcare Capital Partners III, L.P. | 10,412,872 5.600% |
-4,031,572 (-27.91%) |
Filing History |
| 2024-02-14 8:42 pm Purchase |
2023-12-31 | 13G | Pharvaris N.V. PHVS |
Venrock Healthcare Capital Partners III, L.P. | 3,395,606 6.500% |
912,000 (+36.72%) |
Filing History |
| 2024-02-14 8:38 pm Purchase |
2023-12-31 | 13G | Terns Pharmaceuticals, Inc. TERN |
Venrock Healthcare Capital Partners III, L.P. | 4,497,117 7.300% |
789,226 (+21.29%) |
Filing History |
| 2024-02-14 8:28 pm Purchase |
2023-12-31 | 13G | Viridian Therapeutics, Inc. VRDN |
Venrock Healthcare Capital Partners III, L.P. | 5,555,568 9.990% |
1,324,947 (+31.32%) |
Filing History |
| 2024-02-14 8:28 pm Purchase |
2023-12-31 | 13G | Celcuity Inc. CELC |
Venrock Healthcare Capital Partners III, L.P. | 2,476,980 9.990% |
2,476,980 (New Position) |
Filing History |
| 2024-02-14 8:26 pm Purchase |
2023-12-31 | 13G | Adverum Biotechnologies, Inc. ADVM |
Venrock Healthcare Capital Partners III, L.P. | 1,556,421 7.500% |
966,472 (+163.82%) |
Filing History |
| 2024-02-14 8:26 pm Purchase |
2023-12-31 | 13G | Ambrx Biopharma Inc. AMAM |
Venrock Healthcare Capital Partners III, L.P. | 2,070,000 3.300% |
2,070,000 (New Position) |
Filing History |
| 2024-02-14 8:25 pm Purchase |
2023-12-31 | 13G | Abivax S.A. ABVX |
Venrock Healthcare Capital Partners III, L.P. | 3,611,570 5.700% |
298,570 (+9.01%) |
Filing History |
| 2024-02-01 4:15 pm Purchase |
2024-01-22 | 13G | ORIC Pharmaceuticals, Inc. ORIC |
Venrock Healthcare Capital Partners III, L.P. | 4,428,385 6.600% |
4,428,385 (New Position) |
Filing History |
| 2024-01-02 4:16 pm Purchase |
2023-12-21 | 13G | Astria Therapeutics, Inc. ATXS |
Venrock Healthcare Capital Partners III, L.P. | 3,225,806 8.900% |
3,225,806 (New Position) |
Filing History |
| 2023-12-28 4:17 pm Purchase |
2023-12-18 | 13G | Ocular Therapeutix, Inc. OCUL |
Venrock Healthcare Capital Partners III, L.P. | 7,775,760 6.800% |
7,775,760 (New Position) |
Filing History |
| 2023-12-28 4:16 pm Purchase |
2023-12-26 | 13G | KalVista Pharmaceuticals, Inc. KALV |
Venrock Healthcare Capital Partners III, L.P. | 3,573,714 10.300% |
657,047 (+22.53%) |
Filing History |
| 2023-11-30 4:15 pm Purchase |
2023-11-20 | 13G | Pharvaris N.V. PHVS |
Venrock Healthcare Capital Partners III, L.P. | 2,483,606 6.100% |
2,483,606 (New Position) |
Filing History |
| 2023-11-22 4:16 pm Purchase |
2023-10-24 | 13G | Abivax S.A. ABVX |
Venrock Healthcare Capital Partners III, L.P. | 3,313,000 5.300% |
3,313,000 (New Position) |
Filing History |
| 2023-09-29 4:15 pm Purchase |
2023-09-19 | 13G | RayzeBio, Inc. Common Stock RYZB |
Venrock Healthcare Capital Partners III, L.P. | 4,016,847 6.600% |
4,016,847 (New Position) |
Filing History |